Form 4: Emergent BioSolutions SVP Jessica Perl Reports Stock and Options Transactions

Jessica Perl, SVP, General Counsel, and Corporate Secretary of Emergent BioSolutions, reports the acquisition of restricted stock units and employee stock options, as well as the disposal of common stock.

Summary

• Jessica Perl, a Senior Vice President at Emergent BioSolutions Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 6, 2025, Perl acquired 62,500 restricted stock units (RSUs) and 62,500 employee stock options.
• The RSUs vest in three annual installments starting the day prior to the anniversary of the grant date.
• Each RSU represents the right to receive one share of Emergent BioSolutions common stock.
• The employee stock options, with an exercise price of $5.8, also vest in three equal installments beginning on the day prior to the anniversary date of the grant and expire on March 5, 2032.
• Perl also disposed of 68,387 shares of common stock.
• Following these transactions, Perl beneficially owns 68,387 shares of common stock and 95,945 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing primarily reflects routine transactions related to stock options and restricted stock units. The disposal of shares is a slight negative, but without further context, it's difficult to assess the overall impact.

Positives

• The grant of restricted stock units and employee stock options aligns Jessica Perl's interests with the long-term performance of Emergent BioSolutions.
• The vesting schedules for both RSUs and options incentivize continued service with the company.

Negatives

• The disposal of 68,387 shares of common stock could be interpreted negatively by some investors, although the reason for the disposal is not disclosed.

Risks

• The value of the restricted stock units and employee stock options is dependent on the future performance of Emergent BioSolutions' stock.
• Changes in company strategy or market conditions could impact the value of these securities.

Future Outlook

The vesting of the restricted stock units and employee stock options is contingent upon continued service with the company, suggesting an expectation of Perl's continued involvement with Emergent BioSolutions.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to align management incentives with shareholder value.
• Companies like Moderna and BioNTech also utilize similar equity-based compensation plans for their executives.
• The vesting schedules and exercise prices are generally in line with industry norms for companies of similar size and stage of development.

Stakeholder Impact

• The transactions reported in the Form 4 may influence investor sentiment regarding Emergent BioSolutions.
• The vesting of equity awards incentivizes the reporting person to contribute to the company's success, potentially benefiting shareholders and employees.

Key Dates